LAPORAN KASUS LEPAS BANGSAL

DESENSITISASI COTRIMOXAZOL PADA PASIEN

HIV DENGAN RIWAYAT ALERGI COTRIMOXAZOL

Oleh

Dandy Firmansyah

Disetujuitanggal :

dr. Deshinta Putri Mulya, M.Sc, Sp.PD. KAI .............................................

dr. Anna Anggraeni SpPD- KPTI .............................................

Dipresentasikantanggal :

dr. Deshinta Putri Mulya,M.Sc, Sp.PD. KAI.............................................

dr. Anna Anggraeni SpPD- KPTI .............................................

Bagian Ilmu Penyakit Dalam

Fakultas Kedokteran Universitas Gadjah Mada –
Rumah Sakit Umum Pusat dr. Sardjito
Yogyakarta 2018

i
 LEMBAR PENGESAHAN

LAPORAN KASUS LEPAS BANGSAL

DESENSITISASI COTRIMOXAZOL PADA PASIEN

HIV DENGAN RIWAYAT ALERGI COTRIMOXAZOL

Oleh:

Dandy Firmansyah

Dipresentasikan pada tanggal:

Pembimbing I dr. Deshinta Putri Mulya, M.Sc, Sp.PD.KAI paraf:................

Pembimbing II dr. Anna Anggraeni SpPD- KPTI paraf:.............

Penguji I paraf : ..........

Penguji II paraf : .............

Penguji III paraf :.............

Penguji IV paraf : ............

Penguji V paraf :.............

ii
 DAFTAR ISI

HALAMAN JUDUL...............................................................................................i

HALAMAN PENGESAHAN................................................................................ii

DAFTAR ISI..........................................................................................................iii

DAFTAR GAMBAR.............................................................................................iv

DAFTAR TABEL...................................................................................................v

BAB I. PENDAHULUAN.......................................................................................1

BAB II. KASUS .....................................................................................................3

BAB III. PEMBAHASAN....................................................................................14

A. Angioedema

B. Tes Alergi

C. Alergi Obat

BAB IV. KESIMPULAN ....................................................................................36

DAFTAR PUSTAKA.............................................................................................37

iii
 DAFTAR GAMBAR

Gambar 1 Gambaran EKG tanggal 06/05/2017......................................................8

Gambar 2 Hasil Rontgen Thorax tanggal 6/5/2017..................................................9

Gambar 3 Hasil skin prick test pada pasien...........................................................14

Gambar 4 Foto pasien saat perawatan hari ke- 10 (3 hari setelah angioedema

terjadi)....................................................................................................10

Gambar 5 Foto pasien saat perawatan hari ke-15( 8 hari setelah angioedema

terjadi).....................................................................................................14

Gambar 6 Prosedur SPT..........................................................................................30

iv
 DAFTAR TABEL

Tabel 1 Diagnosis Banding Angioedema.......................................................22 - 23

Tabel2.Konsentrasi tes non iritatif untuk antibiotik Betalaktam ..................30-31

v
 DAFTAR PUSTAKA

1. Stokes SC, Tankersley MS. HIV: Practical implications for the practicing allergist–

immunologist. Ann Allergy Asthma Immunol. 2011; 107:1-9.

2. Rancinan C, Morlat P, Chêne G, Guez S, Baquey A, Beylot J, et al. IgE serum level: A

prognostic marker for AIDS in HIV-infected adults? J Allergy Clin Immunol 1998;102:329-

30.

3. Da Silva Linhar L, Kweku Sagoe Amoah S, Da Silva J. Relationship between atopy,

allergic diseases and total serum IgE levels among HIV-infected children. Eur Ann Allergy

Clin Immunol. 2013;(45(5):155-9.

1 French RF, Stewart GJ, Penny R, Levy JA (1997) How HIV

produces immune deficiency: Managing HIV. Med J Aust
164: 166-171.

2. Carr A, Cooper DA, Penny R (1991) Allergic manifestations of

human immunodeficiency virus (HIV) infection. J Clin Immunol 11: 55-
64.

4 Coopman SA, Johnson RA, Platt R (1993) Cutaneous disease and

drug reactions in HIV infection. N Engl J Med 23: 1670-1674.

28. Lin D, Li W, Rieder M. Cotrimoxazole for prophylaxis or treatment

of opportunistic infections of HIV/AIDS in patients with previous history
or hypersensitivity to cotrimoxazole. Cochrane Database Syst Rev
2001; 184: 992-997.

29. Du Toit G, Reynolds L, Eley B. Induction of tolerance after a

serious trimethoprim-sulphamethoxazole reaction in an HIV-infected
child. S Afr Med J 2003; 93: 358-359

vi
 5 Phillips E, Mallal S (2007) Drug hypersensitivity in HIV. CurrOpin Allergy
Clin Immunol 7: 324-330.

7 Chaponda M, Pirmohamed M (2011) Pirmohamed M Hypersensitivity

reactions to HIV therapy. Br J Clin Pharmacol 71: 659-671.

16. Naisbitt DJ, Vilar FJ, Stalford AC, Wilkins EG, Pirmohamed M, et al.
(2000) Plasma cysteine deficiency and decreased reduction of
nitrososulfamethoxazole with HIV infection. AIDS Res Hum Retroviruses
16: 1929-1938.

17. Walmsley SL, Winn LM, Harrison ML, Uetrecht JP, Wells PG, et al. (1997)
Oxidative stress and thio depletion in plasma and peripheral blood
lymphocytes from HIV-infected patients: toxicological and pathological
implications. AIDS 11: 1689-1697.

69. Lee BL, Safrin S. Interactions and toxicities of drugs used in patients with AIDS. Clin

Infect Dis. 1992;14:773–779. IV.

70. Koopmans PP, vanderVen AJ, Vree TB, et al. Pathogenesis of hypersensitivity

reactions to drugs in patients with HIV infection: allergic or toxic? AIDS.

1995;9:217–222. IV.

7. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol Rev.

1993; 57:183-233.

8. Lin RY. Chronic diffuse dermatitis and hyper-IgE in HIV infection. Acta Derm Venerol.

1988;68(6):486-91.

vii
15. Carr A, Cooper DA, Penny R. Allergic manifestations of human immunodeficiency

virus (HIV) infection. J Clin Immunol. 1991;11:55-64.

16. Wright DN, Nelson RP, Ledford DK, et al. Serum IgE and human immunodeficiency

virus (HIV) infection. J Allergy Clin Immunol. 1990;85:445-52.

17. Lucey DR, Zajac RA, Melcher GP, et al. Serum IgE levels in 622 persons with human

immunodeficiency virus infection: IgE elevation with marked depletion of CD4+ T

cells. AIDS Res Hum Retroviruses. 1990;6:427-9.

18. Paganelli R, Scala E, Mezzaroma I, et al. Immunologic aspects of

hyperimmunoglobulinemia E-like syndrome in patients with AIDS. J Allergy Clin

Immunol. 1995;95:995-1003.

19. Bacot BK, Paul ME, Navarro M, Abramson SL, Kline MW, Hanson IC, et al. Objective

measures of allergic disease in children with human immunodeficiency virus

infection. J Allergy Clin Immunol. 1997;100:707-11.

20. Koutsonikolis A, Nelson RP, Fernandez-Caldas E, Brigino EN, Seleznick M, Good RA, et

al. Serum total and specific IgE levels in children infected with human

immunodeficiency virus. J Allergy Clin Immunol. 1996;97:692-7.

71. Carr A, Cooper DA, Penny R. Allergic manifestations of human immunodeficiency

virus (HIV) infection. J Clin Immunol. 1991;11: 55– 64. IV.

72. Carr A, Swanson R, Penny R, et al. Clinical and laboratory markers of hypersensitivity

to trimethoprim-sulphamethoxazole in patients with Pneumocystis carinii

pneumonia and AIDS. J Infect Dis. 1993;167: 180 –185. III.

viii
73. Bayard P, Berger T, Jacobson M. Drug hypersensitivity reactions and human

immunodeficiency virus disease. J Acquir Immune Defic Syndr. 1992;5:1237–1257.

IV.

298. Rieder MJ, Shear NH, Kanee A, et al. Prominence of slow acetylator phenotype

among patients with sulfonamide hypersensitivity reactions. Clin Phamacol Ther

1991;49:13–17. IIa.

498. Carr A, Tindall B, Penny R, et al. In vitro cytotoxicity as a marker of hypresensitivity

to sulphamethoxazole in patients with HIV. Clin Exp Immunol. 1993;94:21–25. III.

499. Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose

trimethoprim sulfamethoxazole in previously hypersensitive HIV infected patients.

AIDS. 1993;7:65–71. IIb.

500. Carr A, Gross AS, Hoskins JM, et al. Acetylation phenotype and cutaneous

hypersensitivity to trimethoprim-sulphamethoxazole in HIVinfected patients.

AIDS. 1994;8:333–337. III.

501. Lehmann DF, Liu A, Newman N, et al. The association of opportunistic infections

with the occurrence of trimethoprim/sulfamethoxazole hypersensitivity in

patients infected with human immunodeficiency virus. J Clin Pharmacol.

1999;39:533–537. III.

502. Lee BL, Wong D, Benowitz NL, et al. Altered patterns of drug metabolism in patients

with acquired immunodeficiency syndrome. Clin Phamacol Ther. 1993;53:529 –

535. III.

ix
503. Walmsley SL, Khorasheh S, Singer J, et al. A randomized trial of N-acetylcysteine for

prevention of trimethoprim-sulfamethoxazole hypersensitivity reactioins in

Pneumocystis carinii pneumonia prophylaxis (CTN 057). J Acquir Immune Defic

Syndr Hum Retrovirol. 1988;19:498 –505. Ib.

504. Rieder MJ, Krause R, Bird IA, et al. Toxicity of sulfonamide-reactive metabolites in

HIV-infected, HTLV-infected, and noninfected cells. J Acquir Immune Defic Syndr.

1995;8:134 –140. III.

505. Battegay M, Opravil M, Wuthrich B, et al. Rash with amoxicillin clavulanate therapy

in HIV-infected patients. Lancet. 1989;2:1100. III.

506. Okwera A, Whalen C, Byekwaso F. Randomized trial of thiacetazone and rifampicin-

containing regimens for pulmonary tuberculosis in HIV-infected Ugandans: The

Makere University-Case Western Reserve University Research Collaboration.

Lancet. 1994;344: 1323–1328. Ib.

72. Carr A, Swanson R, Penny R, et al. Clinical and laboratory markers of hypersensitivity

to trimethoprim-sulphamethoxazole in patients with Pneumocystis carinii

pneumonia and AIDS. J Infect Dis. 1993;167: 180 –185. III.

499. Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose

trimethoprim sulfamethoxazole in previously hypersensitive HIV infected patients.

AIDS. 1993;7:65–71. IIb.

507. Pertel P, Hirschtick R. Adverse reactions to dapsone in persons injected with human

immunodeficiency virus. Clin Infect Dis. 1994;18: 630 – 632. III.

x
508. O’Neil CE, Reed MA, Lopez M, et al. Evaluation of immune parameters in HIV

subjects reporting adverse reactions to sulfamethoxazole. Int Arch Allergy Appl

Immunol. 1991;94:246 –247. III.

509. Daftarian MP, Filion LG, Cameron W, et al. Immune response to sulfamethoxazole

in patients with AIDS. Clin Diagn Lab Immunol. 1995;2:199 –204. III.

74. Absar N, Daneshvar H, Beall G. Desensitization to trimethoprim/ sulfamethoxazole in

HIV-infected patients. J Allergy Clin Immunol. 1994;93:1001–1005. III.

75. Gluckstein D, Ruskin J. Rapid oral desensitization to trimethoprimsulfathoxazole

(TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients

with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis.

1995;20:849 – 853. III.

76. Nguyen M, Weiss PJ, Wallace MR. Two-day oral desensitization to trimethoprim-

sulfamethoxazole in HIV-infected patients. AIDS. 1995; 9:573–575. III.

77. Belchi-Hernandez J, Espinosa-Parra FJ. Management of adverse reactions to

prophylactic trimethoprim-sulfamethoxazole in patients with human

immunodeficiency virus infection. Ann Allergy Asthma Immunol. 1996;76:355–

358. III.

78. Kalanadhabhatta V, Muppidi D, Sahni H, et al. Successful oral desensitization to

trimethoprim-sulfamethoxazole in acquired immune deficiency syndrome. Ann

Allergy Asthma Immunol. 1996;77:394 – 400. III.

xi
79. Caumes E, Guermonprez G, Lecomte C, et al. Efficacy and safety of desensitization

with sulfamethoxazole and trimethoprim in 48 previously hypersensitive patients

infected with human immunodeficiency virus. Arch Dermatol. 1997;133:465– 469.

III.

80. Rich JD, Sullivan T, Greineder D, et al. Trimethoprim/sulfamethoxazole incremental

dose regimen in human immunodeficiency virus-infected persons. Ann Allergy

Asthma Immunol. 1997;79:409 – 414. III.

81. Ryan C, Madalon M, Wortham DW, et al. Sulfa hypersensitivity in patients with HIV

infection: onset, treatment, critical review of the literature. Wis Med J.

1998;97:23–27. III.

82. Demoly P, Messaad D, Sahla H, et al. Six-hour trimethoprimsulfamethoxazole-graded

challenge in HIV-infected patients. J Allergy Clin Immunol. 1998;102(6 pt 1):1033–

1036. III.

83. Bonfanti P, Pusterla L, Parazzini F, et al. The effectiveness of desensitization versus

rechallenge treatment in HIV-positive patients with previous hypersensitivity to

TMP-SMX: a randomized multicentric study. Biomed Pharmacother. 2000;54:45–

49. Ib.

84. Yoshizawa S, Yasuoka A, Kikuchi Y, et al. A 5-day course of oral desensitization to

trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency

virus type-1 infection who were previously intolerant to T/S. Ann Allergy Asthma

Immunol. 2000;85:241–244. III.

xii
85. Moreno JN, Poblete RB, Maggio C, et al. Rapid oral desensitization for sulfonamides

in patients with the acquired immunodeficiency syndrome. Ann Allergy Asthma

Immunol. 1995;74:140 –146. III.

510. Douglas R, Spelman D, Czarny D, et al. Successful desensitization of two patients

who previously developed Stevens-Johnson Syndrome while receiving

trimethoprim-sulfamethoxazole. Clin Infect Dis. 1997; 25:1480. III.

505. Battegay M, Opravil M, Wuthrich B, et al. Rash with amoxicillin clavulanate therapy

in HIV-infected patients. Lancet. 1989;2:1100. III.

506. Okwera A, Whalen C, Byekwaso F. Randomized trial of thiacetazone and rifampicin-

containing regimens for pulmonary tuberculosis in HIV-infected Ugandans: The

Makere University-Case Western Reserve University Research Collaboration.

Lancet. 1994;344: 1323–1328. Ib.

511. Ackerman Z, Levy M. Hypersensitivity reactions to drugs in acquired

immunodeficiency syndrome. Postgrad Med J. 1987;63:55–56. IV.

512. Holtzman DM, Kaku DA, So YT. New-onset seizures associated with human

immunodeficiency virus infection: causation and clinical features in 100 cases. Am

J Med. 1989;87:173–177. III.

513. Jacobson MA, Besch CL, Child C, et al. Toxicity of clindamycin as prophylaxis for

AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical

Research on AIDS. Lancet. 1992;339:333–334. III.

xiii
514. Kennedy C, Goetz M, Mathisen G. Ciprofloxacin-induced anaphylactoid reactions in

patients infected with the human immunodeficiency virus. West J Med.

1990;153:563–564. III.

162. Schnyder B, Pichler WJ. Allergy to sulfonamides. J Allergy

Clin Immunol. 2013;131:256–257.[PubMed]

163. Strom BL, Schinnar R, Apter AJ, Margolis DJ, Lautenbach E,

Hennessy S, Bilker WB, Pettitt D. Absence of cross-reactivity
between sulfonamide antibiotics and sulfonamide
nonantibiotics. N Engl J Med. 2003;349:1628–1635. [PubMed]

164. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T,
Auquier A, Bastuji-Garin S, Correia O, Locati F, et al. Medication
use and the risk of Stevens-Johnson syndrome or toxic epidermal
necrolysis. N Engl J Med. 1995;333:1600–1607. [PubMed]

166. Schmid DA, Campi P, Pichler WJ. Hypersensitivity reactions

to quinolones. Curr Pharm Des. 2006;12:3313–3326. [PubMed]

167. Uetrecht J. Prediction of a new drug's potential to cause

idiosyncratic reactions. Curr Opin Drug Discov Devel. 2001;4:55–
59. [PubMed]

168. Schnyder B, Burkhart C, Schnyder-Frutig K, von Greyerz S,

Naisbitt DJ, Pirmohamed M, Park BK, Pichler WJ. Recognition of
sulfamethoxazole and its reactive metabolites by drug-specific
CD4+ T cells from allergic individuals. J
Immunol. 2000;164:6647–6654. [PubMed]

169. Wolkenstein P, Carrière V, Charue D, Bastuji-Garin S, Revuz

J, Roujeau JC, Beaune P, Bagot M. A slow acetylator genotype is
a risk factor for sulphonamide-induced toxic epidermal

xiv
necrolysis and Stevens-Johnson
syndrome. Pharmacogenetics. 1995;5:25525–25528. [PubMed]

172. Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several

herpesviruses can reactivate in a severe drug-induced

multiorgan reaction in the same sequential order as in graft-

versus-host disease. Br J Dermatol. 2006;155:301–

306. [PubMed]

Jick 1982

Jick H. Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized

patients. Reviews of infectious diseases 1982;4:426-28.

Kovacs 1984

Kovacs JA, Hiemenz JW,Macher AM, Stover D,Murray HW, Shelhamer

J, Lane HC, Urmacher C, Honig C, Longo DL, Parker MM,

Natanson C, Parrillo JE, Fauci AS, Pizzo PA, Masur H. Pneumocystis

carinii pneumonia: A compar-ison between patients with the

acquired immunode_ciency syndrome and patients with other immunode

_ciencies. Annals of internal medicine 1984;100:663-671.

Wharton 1986

xv
Wharton JM, Coleman DL, Wofsy CB, Luce JM, Blumenfeld

W, Hadley WK, Ingram-Drake L, Volberding PA, Hopewell PC.

Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis

carinii pneumonia in the acquired immunode_ciency syndrome. A

prospective randomized trial. Annals of internal medicine 1986;105:

37-44.

Medina 1990

Medina I, Mills J, Leoung G, Hopewell PC, Lee B, Modin G,

Benowitz N,Wofsy CB. Oral therapy for Pneumocystis carinii pneumonia

in the acquired immunode_ciency syndrome. A controlled

trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone.

Oral therapy for Pneumocystis carinii pneumonia in the acquired

immunode_ciency syndrome. A controlled trial of trimethoprim-

sulfamethoxazole versus trimethoprim-dapsone. New England

journal of medicine 1990;323:776-82.

Hughes 1993

Hughes W, Leoung G, Kramer F, Bozzette SA, Safrin S, Frame P,

xvi
Clumeck N, Masur H, Lancaster D, Chan C, Lavelle J, Rosenstock

J, Falloon J, Feinberg J, LaFon S, Rogers M, Sattler F. Comparison of

atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat

Pneumocystis carinii pneumonia in patients with AIDS.NewEngland

journal of medicine 1993;328:1521-7.

Jaffe 1983

Jaffe HS, Abrams DI, Ammann AJ, Lewis BJ, Golden JA. Complications

of co-trimoxazole in treatment of AIDS-associated Pneumocystis

carinii pneumonia in homosexual men. Lancet 1983;2(8359):

1109-1111.

Gordin 1984

Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to

trimethoprim-sulfamethoxazole in patients with the acquired immunode

_ciency syndrome. Annals of internal medicine 1984;100:

495-499.

Small 1985

Small CB, Harris CA, Friedland GH, Klein RS. The treatment of

xvii
Pneumocystis carinii pneumonia in the acquired immunode_ciency

syndrome. Archives of internal medicine 1985;145:837-840.

Fischl 1988

Fischl MA, Dickinson GM, La Voie L. Safety and ef_cacy of sulfamethoxazole

and trimethoprim chemoprophylaxis for Pneumocystis

carinii pneumonia in AIDS. Journal of the American Medical Association

1988;259:1185-9.

Hardy 1992

Hardy WD, Feinberg JD, Finkelstein M, Power ME, HeW, Kaczka

C, Frame PT, Holmes M, Waskin H, Fass RJ, Powderly WG, Steinbigel

RT, Zuger A, Holzman RS. A controlled trial of trimethoprimsulfamethoxazole

or aerosolized pentamidine for secondary prophylaxis

of Pneumocystis carinii pneumonia in patients with the acquired

immunode_ciency syndrome. AIDS Clinical Trials Group Protocol

021. New England journal of medicine 1992;327:1842-1848.

Schneider 1992

Schneider MM, Hoepelman AI, Eeftinck Schattenkerk JK, Nielsen

xviii
TL, van der Graaf Y, Frissen JP, van der Ende IM, Kolsters AF, Borleffs

JC. A controlled trial of aerosolized pentamidine or trimethoprim-

sulfamethoxazole as primary prophylaxis against Pneumocystis

carinii pneumonia in patients with human immunode_ciency virus

infection. The Dutch AIDS Treatment Group. New England journal

of medicine 1992;327:1836-41.

Grimwade 2003

Grimwade K, Swingler, G. Cotrimoxazole prophylaxis for opportunistic

infections in adults with HIV. In: Cochrane Database of Systematic

Reviews, CD003108, 2003.

1. World Health Organization. [August 15, 2014] Guidelines on Co-Trimoxazole

Prophylaxis for HIVRelated Infections Among Children, Adolescents and Adults.

2006. Available at: http://

www.who.int/entity/hiv/pub/guidelines/ctxguidelines.pdf

6. World Health Organization. [August 15, 2013] Consolidated guidelines on the use of

antiretroviral drugs for treating and preventing HIV infection: recommendations

for a public health approach. 2013. Available at:

http://www.who.int/hiv/pub/guidelines/arv2013/.

xix
19. Grimwake K, Sturm A, Nunn J, Mbatha D, Zungu D, Gilks C. Effectiveness

of co-trimoxazole prophylaxis on mortality in adults with tuberculosis in

rural South Africa. AIDS. 2005;19:163–168.[PubMed]

Benson 2004

Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating

opportunistic infections among HIV-exposed and infected children:

recommendations from CDC, the National Institutes of Health, and

the Infectious Diseases Society of America. Morbidity and Mortality

Weekly Report 2004;53:1-112.

Phair 1990

Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C, Saah A. The

risk of Pneumocystis carinii pneumonia among men infected with

human immunode_ciency virus type 1. Multicenter AIDS Cohort

Study Group. New England journal of medicine 1990;322:161-5.

Klatt 1994

Klatt EC, Nichols L, Noguchi TT. Evolving trends revealed by autopsies

of patients with the acquired immunode_ciency syndrome.

565 autopsies in adults with the acquired immunode_ciency syndrome,

xx
Los Angeles, Calif, 1982-1993. Archives of pathology & laboratory

medicine 1994;118:884-90.

UNAIDS 2004

Joint United Nations Programme on HIV/AIDS. UNAIDS 2004

Report on the global AIDS epidemic. UNAIDS 2004 Report on the

global AIDS epidemic. Geneva, Switzerland. UNAIDS, 2004.

Gilks 1990

Gilks CF, Ojoo SA, Ojoo JC, Brindle RJ, Paul J, Batchelor BI, Kimari

JN, Newnham R, Bwayo J, Plummer FA,Warrell DA. Invasive

pneumococcal disease in a cohort of predominantly HIV-1 infected

female sex-workers in Nairobi, Kenya. Lancet 1996;347:718-23.

Abouya 1992

Abouya YL, Beaumel A, Lucas S, Dago-Akribi A, Coulibaly G,

N'Dhatz M, Konan JB, Yapi A, De Cock KM. Pneumocystis carinii

pneumonia. An uncommon cause of death in African patients with

acquired immunode_ciency syndrome. American review of respiratory

disease 1992;145:617-20.

xxi
Grant 1997

Grant AD, Djomand G, Smets P, Kadio A, Coulibaly M, Kakou

A, Maurice C, Whitaker JP, Sylla-Koko F, Bonard D, Wiktor SZ,

Hayes RJ, De Cock KM, Greenberg AE. Profound immunosuppression

across the spectrum of opportunistic disease among hospitalized

HIV-infected adults in Abidjan, Cote d'Ivoire. AIDS 1997;11:

1357-64.

Wannamethee 1998

Wannamethee SG, Sirivichayakul S, Phillips AN, Ubolyam S,

Ruxrungtham K, HanvanichM,PhanuphakP. Clinical and immunological

features of human immunode_ciency virus infection in patients

from Bangkok, Thailand. International journal of epidemiology

1998;27:289-95.

Joshi 2002

Joshi M, Chowdhary AS, Dalal PJ,Maniar JK. Parasitic diarrhoea in

patients with AIDS. Natl Med J India 2002;15:72-4.

McNaghten 1999

xxii
McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW.

Effects of antiretroviral therapy and opportunistic illness primary

chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent

Spectrum of Disease Group. AIDS 1999;13:1687-95.

Kaplan 2000

Kaplan JE, Hanson D, Dworkin MS, Frederick T, Bertolli J, Lindegren

ML, Holmberg S, Jones JL. Epidemiology of human immunode

_ciency virus-associated opportunistic infections in the United

States in the era of highly active antiretroviral therapy. Clinical infectious

diseases 2000;30:S5-14.

Wiktor 1999

Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM,

Maurice C, Djomand G, Ackah A, Domoua K, Kadio A, Yapi A,

Combe P, Tossou O, Roels TH, Lackritz EM, Coulibaly D, De Cock

KM, Coulibaly IM, Greenberg AE. Ef_cacy of trimethoprim-sulphamethoxazole

prophylaxis to decrease morbidity and mortality in

HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire:

xxiii
a randomised controlled trial. Lancet 1999;353:1469-75.

Chintu 2004

Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi

K, Farrelly L, Kaganson N, Zumla A, Gillespie SH, Nunn AJ, Gibb

DM, CHAP trial team. Co-trimoxazole as prophylaxis against opportunistic

infections in HIV-infected Zambian children (CHAP): a

double-blind randomised placebo-controlled trial. Lancet 2004;364:

1865-71.

Mwaungulu 2004

Mwaungulu FB, Floyd S, Crampin AC, Kasimba S,Malema S, Kanyongoloka

H, Harries AD, Glynn JR, Fine PE. Cotrimoxazole prophylaxis

reduces mortality in human immunode_ciency virus-positive

tuberculosis patients in Karonga District,Malawi. Bulletin of the

World Health Organization 2004;82:354-63.

Grimwade 2005

Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, Gilks

CF. Effectiveness of cotrimoxazole prophylaxis on mortality in adults

xxiv
with tuberculosis in rural South Africa. AIDS 2005;19:163-8.

WHO 2006

World Health Organization. Guidelines on co-trimoxazole prophylaxis

for HIV-related infections among children, adolescents and

adults. Geneva, Switzerland. WHO, 2006.

1. Castells M. Rapid desensitization for hypersensitivity reactions to medications.

Immunol Allergy Clin North Am 2009;29:585-606.

2. Castells M, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity

reactions to chemotherapy: outcomes and safety of rapid desensitization in 413

cases. J Allergy Clin Immunol 2008;122:574-80.

1 Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized

patients. JAMA 1998; 279:1200–1205.

5 Abbas A. K., Lichtman A. H., 2003. Immediate Hypersensitivity.Cellular and Molecular

Immonology. Fifth Edition. Boston: WB Saunder Company. Pp: 451-83

1 Turvey SE1, Cronin B, Arnold AD, Dioun AF, 2004. Antibiotic desensitization for

the allergic patient: 5 years of experience and practice.Pubmed. 2004

Apr;92(4):426-32.

xxv